載入中
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
前收盤價
US$19.45
+US$0.78 · +4.18%
盤中時間採用ET。市場資料可能有所延遲。
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
日內區間
目前US$19.45
52週區間
目前US$19.45
盤中時間採用ET。市場資料可能有所延遲。
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
日內區間
目前US$19.45
52週區間
目前US$19.45
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 3.31億 USD | 1.08億 USD | 4866.1萬 USD |
| 銷貨成本 | 1118.3萬 USD | — | — | — | — |
| 毛利 | −1118.3萬 USD | — | 3.31億 USD | 1.08億 USD | 4866.1萬 USD |
| 研究與開發 | 4.19億 USD | 3.96億 USD | 4.24億 USD | 3.59億 USD | 2.65億 USD |
| 銷售、一般及管理費用 | 9710.4萬 USD | 1.05億 USD | 1.03億 USD | 9047.5萬 USD | 7905.9萬 USD |
| 營業費用 | 5.44億 USD | 4.87億 USD | 5.27億 USD | 4.49億 USD | 3.44億 USD |
| 利息收入 | 4290.4萬 USD | 6463.6萬 USD | 5150.5萬 USD | 1477.4萬 USD | 459.5萬 USD |
| 折舊和攤銷 | 1481.2萬 USD | 899.2萬 USD | 1672.6萬 USD | 1038.3萬 USD | 859.3萬 USD |
| 營業利益 | −5.55億 USD | −4.87億 USD | −1.97億 USD | −3.41億 USD | −2.96億 USD |
| 淨利 | −5.13億 USD | −4.23億 USD | −1.45億 USD | −3.26億 USD | −2.91億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.02億0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB7370.42萬0.04%1853億 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM7239.12萬0.09%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI5781.37萬0.59%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK4244.06萬0.09%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF4157.23萬0.04%954億 USD0.05%US$235+0.80%
T. Rowe Capital Appreciation Equity ETFTCAF2546.02萬0.28%91.1億 USD0.31%US$43.59+0.90%
Dimensional - US Small Cap ETFDFAS2177.15萬0.06%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
